THE USE OF LEUKOCYTE-REDUCED BLOOD COMPONENTS

被引:21
作者
MILLER, JP [1 ]
MINTZ, PD [1 ]
机构
[1] UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA
关键词
D O I
10.1016/S0889-8588(18)30110-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many of the risks and discomforts associated with blood transfusion may be avoided by removing the contaminating leukocytes from cellular blood components. Leukocyte reduction prevents many febrile reactions that occasionally occur following red cell transfusion and prevents some febrile reactions following platelet transfusion. Prophylactic use of leukocyte-reduced components may prevent primary HLA alloimmunization, which is a principle cause of the refractoriness to platelet transfusion seen in many multiply transfused, thrombocytopenic patients. Leukocyte-reduced components are equally effective in the prevention of CMV as seronegative blood.
引用
收藏
页码:69 / 90
页数:22
相关论文
共 168 条
[21]  
BLUMBERG N, 1993, TRANSFUSION, V33, pS83
[22]  
BLUMBERG N, 1993, TRANSFUSION, V33, pS84
[23]   IMMUNOSUPPRESSIVE EFFECTS OF ALLOGENEIC BLOOD-TRANSFUSIONS - IMPLICATIONS FOR THE PATIENT WITH A MALIGNANCY [J].
BORDIN, JO ;
BLAJCHMAN, MA .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1995, 9 (01) :205-218
[24]  
BORDIN JO, 1994, BLOOD, V84, P344
[25]   EXPERIMENTAL ANIMAL-MODEL OF REFRACTORINESS TO DONOR PLATELETS - THE EFFECT OF PLASMA REMOVAL AND THE EXTENT OF WHITE CELL-REDUCTION ON ALLOGENEIC ALLOIMMUNIZATION [J].
BORDIN, JO ;
BARDOSSY, L ;
BLAJCHMAN, MA .
TRANSFUSION, 1993, 33 (10) :798-801
[26]  
Bowden R.A., 1989, TRANSFUSION S, V29, P57
[27]   CYTOMEGALOVIRUS IMMUNE GLOBULIN AND SERONEGATIVE BLOOD PRODUCTS TO PREVENT PRIMARY CYTOMEGALOVIRUS-INFECTION AFTER MARROW TRANSPLANTATION [J].
BOWDEN, RA ;
SAYERS, M ;
FLOURNOY, N ;
NEWTON, B ;
BANAJI, M ;
THOMAS, ED ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (16) :1006-1010
[28]  
BOWDEN RA, 1991, BLOOD, V78, P246
[29]  
BOWDEN RA, 1993, BLOOD, V82, pA204
[30]  
BRACEY A, 1994, 23 C ISBT ABSTR, P13